Trevi Therapeutics, Inc. TRVI
Set alert
13.56 USD -0.25 -1.81%
At close
13.56 0.00 0.00%
Pre-market · Nov 2, 4:06 AM ET
13.44 Day range 13.91
9.82 52-week range 20.22
- YTD
- +8.31%
- 1 year
- +21.40%
- Open
- 13.78
- Prev close
- 13.81
- Mkt cap
- 1.93B
- Vol
- 1.73M
- Avg vol
- 1.95M
- EPS
- -0.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.44
- High
- 13.91
- Forward P/E
- -23.50
- Beta
- 0.98
- Short ratio
- 5.94
- Inst. own
- 109.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 14.79
- 200-d avg
- 14.33
- 1y target
- 28.18
6M chart
Events in this range
- May 5, 2026Earnings: -0.09; estimate -0.07; surprise -28.57%
- Jul 20, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 20, 2026Rating: B. Riley Securities · Buy → Buy
- Jul 21, 2026Rating: BMO Capital · Outperform → Outperform
- Aug 6, 2026Earnings: -0.11; estimate -0.10946; surprise -0.49%
- Aug 7, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 7, 2026Rating: Oppenheimer · Outperform → Outperform
- Aug 14, 2026Rating: Jones Trading · Buy → Buy
Signals (20)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 14, 2026 | 5 months ago |
Key statistics
- Market cap
- 1.93B
- Enterprise value
- 1.65B
- Trailing P/E
- 0.00
- Forward P/E
- -23.50
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.01
- EPS (TTM)
- -0.35
- Beta
- 0.98
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -33.28M
- Total cash
- 318.87M
- Total debt
- 605.00K
- Return on equity
- -19.66%
- Shares outstanding
- 142.48M
- Short % of float
- 12.47%
- 50-day average
- 14.79
- 200-day average
- 14.33
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 28.18 +107.8% upside
Now 13.56
- Target (low)
- 23.00
- Target (mean)
- 28.18
- Target (high)
- 40.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy2
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.133.
Financials — quick view
TRVI Revenue — quarterly 0
TRVI Net income — quarterly -17.80M
TRVI EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.13167 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.10946 | -0.11 | 0.00 | -0.49% |
| May 5, 2026 | Mar 31, 2026 | -0.07 | -0.09 | -0.02 | -28.57% |
| Mar 17, 2026 | Dec 31, 2025 | -0.10 | -0.06 | +0.04 | +40.00% |
| Nov 13, 2025 | Sep 30, 2025 | -0.10 | -0.08 | +0.02 | +20.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.10 | -0.09 | +0.01 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | Jones Trading | main | Buy | Buy |
| Aug 7, 2026 | Oppenheimer | main | Outperform | Outperform |
| Aug 7, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jul 21, 2026 | BMO Capital | init | Outperform | Outperform |
| Jul 20, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- trevitherapeutics.com
News
Your note
Sign in to keep a note on TRVI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| GOOD JENNIFER L | Chief Executive Officer | Sale | Mar 20, 2025 | 213,313 |
| MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 9.28% | 13,222,228 | 179.29M | Jun 29, 2026 |
| FMR, LLC | 8.82% | 12,562,839 | 170.35M | Jun 29, 2026 |
| Blackrock Inc. | 7.83% | 11,155,026 | 151.26M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 6.98% | 9,939,447 | 134.78M | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.99% | 5,684,592 | 77.08M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.88% | 5,530,675 | 75.00M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 4,047,125 | 54.88M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.98% | 2,819,880 | 38.24M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.87% | 2,660,000 | 36.07M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.67% | 2,374,785 | 32.20M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.37% | 1,950,341 | 26.45M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 1,353,312 | 18.35M | Jun 29, 2026 |